11 min

A Multidisciplinary Approach to Anemia Management in High-Risk MDS and AML CANCER BUZZ

    • Science

Anemia can negatively affect quality of life and treatment outcomes for patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia. In this episode, CANCER BUZZ speaks with Amy DeZern, MD, MHS, director, Bone Marrow Failure and MDS Program, Johns Hopkins University School of Medicine in Baltimore, Maryland, Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, clinical oncology pharmacy manager, Atrium Health Levine Cancer in Charlotte, North Carolina, and David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center in Tampa, Florida. Their discussion elucidates an array of patient-centered approaches, touches on social determinants of health, and highlights collaborative measures to support care coordination in the management of anemia in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia.
 
“It really does take a village to manage the anemia of high-risk MDS…We as providers need to think through transfusion mitigation strategies but also keep our patients safe.” –Amy DeZern, MD, MHS
 
“Health disparities can play a really important role in affecting outcomes. And a lot of that is multifactorial—it may be due to patients without insurance having a higher tendency to delay seeking care due to the associated cost of seeking medical attention, and therefore they may present sicker.”—Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP
“There’s no question, especially as therapies are getting more complex, and the side effects as far as the severity of cytopenias are increasing, this collaboration between blood bank centers and community oncologists is going to be increasingly important.”—David Sallman, MD
Amy DeZern, MD, MHS
Director, Bone Marrow Failure and MDS Program
Professor of Oncology and Medicine
Johns Hopkins University School of Medicine
Baltimore, MD
 
Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP
Clinical Oncology Pharmacy Manager
Atrium Health Levine Cancer
Charlotte, NC
 
David Sallman, MD
Assistant Member, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida
 
This episode was developed in connection with an initiative of the ACCC education program Myelodyplastic Syndromes, Optimal Management of Anemia in Adults with High-Risk MDS, which is supported by Gilead.
 
Resources:
Myelodysplastic Syndromes - ACCC
Achieving & Maintaining Better Outcomes for Patients with Acute Myeloid Leukemia Project - ACCC
Disparities in Acute Myeloid Leukemia - ACCC
 

Anemia can negatively affect quality of life and treatment outcomes for patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia. In this episode, CANCER BUZZ speaks with Amy DeZern, MD, MHS, director, Bone Marrow Failure and MDS Program, Johns Hopkins University School of Medicine in Baltimore, Maryland, Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, clinical oncology pharmacy manager, Atrium Health Levine Cancer in Charlotte, North Carolina, and David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center in Tampa, Florida. Their discussion elucidates an array of patient-centered approaches, touches on social determinants of health, and highlights collaborative measures to support care coordination in the management of anemia in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia.
 
“It really does take a village to manage the anemia of high-risk MDS…We as providers need to think through transfusion mitigation strategies but also keep our patients safe.” –Amy DeZern, MD, MHS
 
“Health disparities can play a really important role in affecting outcomes. And a lot of that is multifactorial—it may be due to patients without insurance having a higher tendency to delay seeking care due to the associated cost of seeking medical attention, and therefore they may present sicker.”—Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP
“There’s no question, especially as therapies are getting more complex, and the side effects as far as the severity of cytopenias are increasing, this collaboration between blood bank centers and community oncologists is going to be increasingly important.”—David Sallman, MD
Amy DeZern, MD, MHS
Director, Bone Marrow Failure and MDS Program
Professor of Oncology and Medicine
Johns Hopkins University School of Medicine
Baltimore, MD
 
Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP
Clinical Oncology Pharmacy Manager
Atrium Health Levine Cancer
Charlotte, NC
 
David Sallman, MD
Assistant Member, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida
 
This episode was developed in connection with an initiative of the ACCC education program Myelodyplastic Syndromes, Optimal Management of Anemia in Adults with High-Risk MDS, which is supported by Gilead.
 
Resources:
Myelodysplastic Syndromes - ACCC
Achieving & Maintaining Better Outcomes for Patients with Acute Myeloid Leukemia Project - ACCC
Disparities in Acute Myeloid Leukemia - ACCC
 

11 min

Top Podcasts In Science

Something You Should Know
Mike Carruthers | OmniCast Media | Cumulus Podcast Network
Technically Speaking: An Intel Podcast
iHeartPodcasts
Radiolab
WNYC Studios
Hidden Brain
Hidden Brain, Shankar Vedantam
Ologies with Alie Ward
Alie Ward
Science Vs
Spotify Studios